RY 156.04 -0.032% TD 79.81 -0.4615% SHOP 99.81 0.9303% CNR 158.79 0.6401% ENB 53.84 0.4478% CP 111.87 0.8019% BMO 112.71 0.7419% TRI 225.62 0.396% CNQ 50.46 2.4777% BN 67.8 1.194% ATD 76.93 -1.0674% CSU 4321.5298 0.3257% BNS 67.27 1.3102% CM 78.76 1.5603% SU 54.66 -1.1037% TRP 62.42 1.2162% NGT 70.54 0.2558% WCN 251.32 0.3153% MFC 36.65 -0.0818% BCE 47.21 0.3187%
Last update at 2024-08-30T16:24:00Z
Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Income before tax | -1.50147M | -2.35933M | -0.23209M | -1.25427M | -0.06820M |
Minority interest | - | - | - | - | - |
Net income | -1.50147M | -2.35933M | -0.23209M | -1.25427M | -0.06820M |
Selling general administrative | 7.12M | 5.79M | 3.76M | 4.03M | 3.68M |
Selling and marketing expenses | - | - | - | - | - |
Gross profit | 7.81M | 4.83M | 3.47M | 3.55M | 4.59M |
Reconciled depreciation | 0.87M | 0.65M | 0.59M | 0.39M | 0.78M |
Ebit | - | -2.55037M | -1.16340M | -1.07948M | 0.09M |
Ebitda | -0.46927M | -1.90168M | -0.57386M | -0.69361M | 0.86M |
Depreciation and amortization | - | - | - | - | - |
Non operating income net other | - | - | - | - | - |
Operating income | -1.34341M | -2.55037M | -1.16340M | -1.07948M | 0.09M |
Other operating expenses | - | - | - | - | - |
Interest expense | 0.16M | 0.00000M | 0.00000M | 0.17M | 0.15M |
Tax provision | - | - | - | - | - |
Interest income | - | - | - | - | - |
Net interest income | -0.16360M | -0.15910M | -0.08771M | -0.17401M | -0.14758M |
Extraordinary items | - | - | - | - | - |
Non recurring | - | - | - | - | - |
Other items | - | - | - | - | - |
Income tax expense | - | - | - | - | - |
Total revenue | 14.88M | 10.54M | 8.65M | 11.15M | 8.68M |
Total operating expenses | 16.22M | 13.10M | 9.81M | 12.23M | 8.59M |
Cost of revenue | 7.07M | 5.71M | 5.18M | 7.61M | 4.09M |
Total other income expense net | 0.00554M | 0.35M | 1.02M | -0.00078M | -0.01205M |
Discontinued operations | - | - | - | - | - |
Net income from continuing ops | -1.50147M | -2.35933M | -0.23209M | -1.25427M | -0.06820M |
Net income applicable to common shares | - | -2.35933M | -0.23209M | -1.25427M | -0.06820M |
Preferred stock and other adjustments | - | - | - | - | - |
Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Total assets | 10.12M | 10.56M | 7.16M | 6.67M | 6.84M |
Intangible assets | 0.88M | 0.85M | 0.87M | 0.84M | 0.85M |
Earning assets | - | - | - | - | - |
Other current assets | - | - | - | - | - |
Total liab | 5.81M | 4.99M | 3.87M | 4.91M | 3.88M |
Total stockholder equity | 4.32M | 5.57M | 3.28M | 1.77M | 2.96M |
Deferred long term liab | - | - | - | - | - |
Other current liab | - | - | - | - | - |
Common stock | - | 25.09M | 22.01M | 20.67M | 20.66M |
Capital stock | 25.22M | 25.09M | 22.01M | 20.67M | 20.66M |
Retained earnings | -24.09472M | -22.59325M | -20.23393M | -20.00184M | -18.71420M |
Other liab | - | - | - | - | - |
Good will | - | - | - | - | - |
Other assets | - | - | - | - | - |
Cash | 0.42M | 3.17M | 1.71M | 0.44M | 0.86M |
Cash and equivalents | - | - | - | - | - |
Total current liabilities | 3.03M | 2.63M | 1.56M | 2.52M | 1.90M |
Current deferred revenue | - | - | - | - | - |
Net debt | 1.99M | - | 0.46M | 1.69M | 1.16M |
Short term debt | - | - | - | - | - |
Short long term debt | - | 0.01M | 0.03M | 0.03M | - |
Short long term debt total | - | - | - | - | - |
Other stockholder equity | - | 3.08M | 1.51M | 1.10M | 1.01M |
Property plant equipment | - | 1.30M | 1.09M | 1.16M | 0.77M |
Total current assets | 7.33M | 8.41M | 5.20M | 4.68M | 5.22M |
Long term investments | - | - | - | - | - |
Net tangible assets | - | 4.71M | 2.41M | 0.93M | 2.10M |
Short term investments | - | - | - | - | - |
Net receivables | 3.67M | 2.67M | 1.66M | 2.44M | 1.58M |
Long term debt | 2.42M | 2.27M | 2.14M | 2.10M | 2.02M |
Inventory | 3.05M | 1.89M | 1.60M | 1.53M | 2.56M |
Accounts payable | 2.83M | 2.45M | 1.53M | 2.49M | 1.87M |
Total permanent equity | - | - | - | - | - |
Noncontrolling interest in consolidated entity | - | - | - | - | - |
Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
Accumulated other comprehensive income | - | - | - | - | - |
Additional paid in capital | - | - | - | - | - |
Common stock total equity | - | - | - | - | - |
Preferred stock total equity | - | - | - | - | - |
Retained earnings total equity | - | - | - | - | - |
Treasury stock | - | - | - | - | - |
Accumulated amortization | - | - | - | - | - |
Non currrent assets other | - | - | - | - | 1.62M |
Deferred long term asset charges | - | - | - | - | - |
Non current assets total | 2.79M | 2.16M | 1.96M | 1.99M | 1.62M |
Capital lease obligations | 0.55M | 0.09M | 0.17M | 0.28M | - |
Long term debt total | - | - | - | - | - |
Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Investments | -0.87321M | -0.72061M | -0.55464M | -0.28387M | -0.27888M |
Change to liabilities | - | 1.04M | -0.40360M | 0.50M | 0.13M |
Total cashflows from investing activities | - | -0.72061M | -0.55464M | -0.28387M | -0.27888M |
Net borrowings | - | -0.19349M | -0.14207M | -0.13362M | -0.03000M |
Total cash from financing activities | -0.31815M | 4.31M | 1.51M | -0.12862M | 0.69M |
Change to operating activities | - | -0.44343M | 0.03M | -0.04292M | 0.25M |
Net income | -1.50147M | -2.35933M | -0.23209M | -1.25427M | -0.06820M |
Change in cash | -2.74917M | 1.46M | 1.27M | -0.41176M | 0.84M |
Begin period cash flow | 3.17M | 1.71M | 0.44M | 0.86M | 0.01M |
End period cash flow | 0.42M | 3.17M | 1.71M | 0.44M | 0.86M |
Total cash from operating activities | -1.55782M | -2.12935M | 0.31M | 0.00073M | 0.44M |
Issuance of capital stock | 0.00000M | 5.12M | 1.70M | 0.00500M | 0.74M |
Depreciation | 0.87M | 0.65M | 0.59M | 0.39M | 0.78M |
Other cashflows from investing activities | - | - | - | - | - |
Dividends paid | - | - | - | - | - |
Change to inventory | -1.16453M | -0.33360M | -0.31589M | 0.10M | -0.10045M |
Change to account receivables | - | -1.01005M | 0.78M | -0.85883M | -0.77278M |
Sale purchase of stock | - | - | - | - | - |
Other cashflows from financing activities | - | 0.88M | 0.27M | 0.27M | -0.02427M |
Change to netincome | - | 0.33M | -0.14433M | 1.17M | 0.21M |
Capital expenditures | 0.87M | 0.72M | 0.51M | 0.29M | 0.29M |
Change receivables | - | - | - | - | - |
Cash flows other operating | - | - | - | - | - |
Exchange rate changes | - | - | - | - | - |
Cash and cash equivalents changes | - | - | - | - | - |
Change in working capital | -1.35888M | -0.74449M | 0.10M | -0.29899M | -0.48682M |
Stock based compensation | 0.14M | 0.14M | 0.09M | 0.09M | - |
Other non cash items | 0.23M | 0.14M | -0.48615M | 0.14M | 0.14M |
Free cash flow | -2.43102M | -2.84996M | -0.24507M | -0.28599M | 0.14M |
Sector: Healthcare Industry: Medical Devices
Company | Change (CAD) | Price (CAD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
---|---|---|---|---|---|---|---|---|
ASG Aurora Spine Corp |
0.01 6.12% | 0.26 | - | - | 1.83 | 5.11 | 2.14 | -31.4665 |
PINK Perimeter Medical Imaging AI Inc |
-0.02 6.06% | 0.31 | - | - | 117.72 | 2.89 | 122.12 | -4.2252 |
VPT VentriPoint Diagnostics Ltd |
-0.01 5.00% | 0.19 | - | - | 1376.49 | 34.01 | 1193.16 | -9.1712 |
TLT Theralase Technologies Inc. |
-0.005 2.63% | 0.18 | - | - | 35.41 | 23.10 | 36.69 | -9.1528 |
NGMD NuGen Medical Devices Inc |
- -% | 0.10 | - | - | 107.75 | 9.71 | 118.72 | -4.5025 |
Aurora Spine Corporation, through its subsidiary, Aurora Spine, Inc., engages in the development and distribution of minimally invasive interspinous fusion systems and devices in Canada. The company offers interspinous process lumbar fusion devices, such as the ZIP, ZIP ULTRA, ZIP LP, and ZIP-51 for patients suffering from degenerative disc diseases; and Ti-Coated polyether ether ketone interbody cages, which provide spacing and stability between the vertebrae while bone grows to complete the fusion process. It also provides sterile-packed titanium plasma spray coated spinal infusion implants for bone growth, as well as interbody products, such as EOS, VOX, Echo, Echo SD, and EchoXL for the lumbar section of the spine, and discovery for cervical procedures. In addition, the company provides SOLO, an anterior lumbar interbody fusion 3D printed stand-alone fusion device, which is an integrated plate and spacer system that helps to preserve the natural anatomic profile while providing spinal column support and stability; and SiLo, a posterior fusion device for the sacroiliac joint. Further, it offers DEXA-C, a cervical interbody system, which is a porous 3D-printed intervertebral body fusion device that incorporates low-, mid-, or high-density lattice pattern options to support the matching of patients' bone quality, as well as DEXA SOLO-L spinal fusion system. Aurora Spine Corporation was founded in 2013 and is headquartered in Toronto, Canada.
20 Holly Street, Toronto, ON, Canada, M4S 3B1
Name | Title | Year Born |
---|---|---|
Mr. Trent J. Northcutt | Founder, Pres, CEO & Director | 1967 |
Mr. Chad Clouse | Chief Financial Officer | NA |
Mr. Laszlo Garamszegi | CTO & Founder | 1971 |
Mr. David M. Meyer | VP, Chief Legal Officer & Sec. | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.